Resources Blog Drug Delivery Systems for Antibody-Based Therapies

Drug Delivery Systems for Antibody-Based Therapies

Biointron 2024-01-17 Read time: 2 mins
Image credit: DOI: 10.1038/s41551-021-00698-w

Antibody-based therapies have emerged as powerful tools in the fight against cancer, providing targeted treatment options with reduced side effects. To further enhance their efficacy, researchers have been exploring the use of drug delivery systems (DDS) for the controlled release of antibodies. DDS would produce various benefits in drug efficacy, including improved convenience, reduced toxicity, and enhanced treatment outcomes.1 With the advancement of nanotechnology and increasing focus on antibody-related dosage forms, the development of advanced antibody delivery systems holds promise for cancer patients. 

Typically, antibody-based drugs are administered through intravenous routes, although there are risks with infusion-related reactions. To improve patient medication convenience, DDSs controlled release may use strategies such as subcutaneous injections, local depot formulations, inhalation powders, and oral systems.2 Another example are hydrogels, which studies have shown to be a potential DDS, controlling the release of antibody-streptavidin conjugates from the agarose-desthiobiotin hydrogels via controlled dissolution of sparingly soluble biotin derivatives.3 

At Biointron, we are dedicated to accelerating antibody discovery, optimization, and production. Our team of experts can provide customized solutions that meet your specific research needs. Contact us to learn more about our services and how we can help accelerate your research and drug development projects. 


  1. Chen, Z., Kankala, R. K., Yang, Z., Li, W., Xie, S., Li, H., Chen, Z., & Zou, L. (2022). Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects. Theranostics, 12(8), 3719-3746.

  2. Ibeanu, N., Egbu, R., Onyekuru, L., Javaheri, H., Khaw, P. T., Williams, G. R., Brocchini, S., & Awwad, S. (2020). Injectables and Depots to Prolong Drug Action of Proteins and Peptides. Pharmaceutics, 12(10). 

  3. Huynh, V., & Wylie, R. G. (2018). Competitive Affinity Release for Long-Term Delivery of Antibodies from Hydrogels. Angewandte Chemie International Edition, 57(13), 3406-3410.

Subscribe to our Blog

Recent Blog

Computational antibody methods schematic. DOI: 10.1093/bib/bbz095The development of therapeutic antibodies has been significantly enhanced by advancements in computational methods and artificial intelligence (AI). These technologies have streamlined the antibody discovery process, improving the abil

May 27, 2024

Welcometo Antibody Basics by Biointron,Part 8. In this episode, we’ll talk about therapeutics targeting cancer.What is cancer immunotherapy?Cancer immunotherapy leverages the body's immune system to fight cancer more selectively and effectively than traditional methods such as chemotherapy

May 24, 2024

The generation of an immune response to a vaccine. DOI: 10.1038/s41577-020-00479-7Vaccination is one of the most effective tools in preventing infectious diseases. At its core, the success of a vaccine hinges on its ability to induce a robust and lasting antibody response against a specific pathogen

May 22, 2024

Innovation orientation and goals for transforming CAR-T cell engineering. DOI: 10.1186/s13045-020-00910-5Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary cancer treatment in which engineered CARs redirect lymphocytes, typically T cells, to recognize and destroy cells expressing a sp

May 20, 2024

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.